The Wales Life Science Fund has led a €12 million Series B funding round for drug developer Apitope in order to enable to company to progress its pipeline of peptide-based therapeutics directed at autoimmune and allergic diseases. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
